FindTrial
Sign In

Effect of dexmedetomidine as an adjuvant on the EC50 of ropivacaine in transversus abdominis plane block

Effect of dexmedetomidine as an adjuvant on the EC50 of ropivacaine in transversus abdominis plane block

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072556
Enrollment
Unknown
Registered
2023-06-16
Start date
2023-06-30
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Interventions

group C:ropivacaine 20ml
group D:0.5 µg/kg dexmedetomidine + ropivacaine mixture 20ml

Sponsors

First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) classification: I-III; aged 18-80 years, ready for laparoscopic right hemicolectomy under general anesthesia, and no contraindication to regional anesthetic block.

Exclusion criteria

Exclusion criteria: Infection at the proposed site of block; allergy to local anesthetic drug, coagulation disorders, body mass index (BMI) > 35 kg/m2, cognitive impairment, speech and hearing impairment, chronic pain, renal or hepatic failure and history of opioid abuse.

Design outcomes

Primary

MeasureTime frame
mean arterial pressure;heart rate;VAS scores;effective concentration;—

Secondary

MeasureTime frame
postoperative complications;—

Countries

China

Contacts

Public ContactJinlong Liu

Department of Anesthesiology. First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi,P.R.China

Ljl99488@163.com+86 137 6771 5346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026